GSK Gets Boost As Shingles Vaccine Enters Late Stage. AGEN Goes Along For Ride. (GSK, AGEN)
GlaxoSmithKline’s (NYSE: GSK) new shingles recently entered phase III trials, and is expected to breeze through these as well. Meanwhile, Antigenics Inc. (NYSE: AGEN) the company responsible for the vaccine’s adjuvant, also experienced a major jump yesterday. Shares of GSK are up .56% today to $37.63. Shares of AGEN are down 3.68% to $0.82, but this should be seen as more of a minor correction after gaining nearly 12% yesterday.
AGEN has traded 508 thousand shares today so far, with an average volume of 557 thousand.
-Michael B. Sauter
